New hope for Tough-to-Treat ovarian cancer: experimental drug trial opens
NCT ID NCT06964009
Summary
This early-stage study aims to find the safest and most effective dose of an experimental drug called DT2216 when given with standard chemotherapy (paclitaxel) for women with recurrent ovarian cancer that has stopped responding to platinum-based treatments. The trial will enroll about 30 participants to carefully monitor side effects and see how well the combination works. Researchers hope this new approach, which targets a protein that helps cancer cells survive, could offer a new option for this difficult-to-treat condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center (BIDMC)
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
Contact
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.